Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Pepti
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Pepti: October 2026
vs
Verdict72/ 100
Grade C · #119Pepti
Dose-dependent compounded care billed every four weeks, starting at $99 per supply for semaglutide and $159 for tirzepatide.
Visit PeptiThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 72/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Pepti still earns its place — patients who want a published dose ladder and will compare the full cost of four-week billing.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results75
92
Real-world results75
97Price honesty64
97
Price honesty64
96Prescriber access84
96
Prescriber access84
88Formulary choice88
88
Formulary choice88
95Cancellation fairness38
95
Cancellation fairness38
93Member support79
93
Member support79
Price, coverage & features
| Metric | CoreAge Rx | Pepti |
|---|---|---|
| Verdict Score | 94/100 | 72/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $107.25/mo equivalent (starter dose, compounded; 4-week billing) |
| Tirzepatide | $149/mo | From $172.25/mo equivalent (starter dose, compounded; 4-week billing) |
| Coverage | All 50 states | All 50 states (treatment eligibility varies) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Pepti
What we like
- Publishes prices for each injection dose
- Offers both injectable molecules and a separate oral catalog
- Explains treatment-specific state eligibility
The caveats
- Four-week billing produces 13 payments per 52 weeks; monthly equivalents use 13 payments divided by 12
- Starting doses cost less than higher doses
- Compounded medicines are not FDA-approved
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Patients who want a published dose ladder and will compare the full cost of four-week billing.
Visit Pepti Read the full Pepti review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Pepti does the reverse.
More on CoreAge Rx
More on Pepti
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.